Rapamycin improved brain blood flow in middle-aged APOE4 carriers in a Missouri-led study
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
University of Missouri School of Medicine researcher Ai-Ling Lin and colleagues report that rapamycin—a transplant-rejection drug studied for aging—raised cerebral blood flow in cognitively healthy middle-aged people carrying the Alzheimer’s-linked APOE4 variant after four weeks of low-dose treatment, with the largest gains among women. Reduced perfusion can precede memory decline by years, so the team frames improved blood flow as a possible early target for delaying onset.
Continue in the app — vote & join in ➔Source: ScienceDaily · via ahirlevel.hu